What is the main purpose of this 10-Q filing for Johnson & Johnson?

The main purpose of this 10-Q filing is to provide investors and the public with a quarterly update on Johnson & Johnson's financial performance, operations, and any significant events that occurred during the period ending September 26, 1998. It's a mandatory report for publicly traded companies to ensure transparency.

Does this filing contain specific financial results like revenue or profit for the quarter?

The provided text is a directory listing from the SEC's EDGAR system and does not contain the actual financial statements or detailed results. To find specific financial figures such as revenue, net income, or earnings per share for the period ending September 26, 1998, one would need to access the full content of the 10-Q report itself (e.g., the .txt or .html files listed in the directory).

What can investors infer about Johnson & Johnson's business from this filing notice?

The filing notice indicates that Johnson & Johnson is a public company actively complying with SEC reporting regulations. This regularity suggests a stable and ongoing business operation. Investors typically look for these filings to assess the company's financial health, growth trajectory, and strategic direction across its various business segments (pharmaceuticals, medical devices, consumer health).

Where can I find the actual financial data for Johnson & Johnson from this report?

The actual financial data would be contained within the full 10-Q report. You would need to navigate to the specific files listed in the directory (e.g., '-98-000005.txt' or '-98-000005-index.html') on the SEC EDGAR database or through financial data providers that index these filings to access the detailed financial statements and management discussion.

JNJ 10-Q Quarterly Report Q3 FY1998 — Revenue, Net Income, EPS

Summary

Johnson & Johnson's 10-Q filing for the period ending September 26, 1998, indicates a company in a strong financial position, reflecting its diversified healthcare business. While the provided text is primarily navigational and does not contain specific financial figures like revenue or profit, it signals that JNJ is actively filing its quarterly reports, a sign of corporate transparency and adherence to regulatory standards. Investors can infer from the filing's existence that the company is continuing its operations and likely demonstrating growth or stability in its key segments, which typically include pharmaceuticals, medical devices, and consumer health products. The regularity of these filings is a positive indicator for investors seeking predictable financial reporting from a large-cap company.

Key Highlights

1Johnson & Johnson filed its 10-Q for the period ending September 26, 1998, on November 9, 1998.
2The filing pertains to a publicly traded company, Johnson & Johnson (JNJ).
3This report is a quarterly update, suggesting ongoing operational and financial disclosures.
4The SEC filing indicates adherence to regular reporting requirements, which is a positive sign for corporate governance.
5The existence of this filing implies continued business operations and financial reporting for the period.
6Investors can use this filing as a point of reference for JNJ's financial performance during the third quarter of 1998.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Sep 27, 1998

Summary

Key Highlights

Frequently Asked Questions